What is the role of meropenem/vaborbactam (Vabomere) in the treatment of Klebsiella infections?

Updated: Jun 10, 2019
  • Author: Shahab Qureshi, MD, FACP; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print
Answer

The novel carbapenem/beta-lactamase inhibitor meropenem/vaborbactam (Vabomere) specifically addresses carbapenem-resistant Enterobacteriaceae (CRE) (eg, E coli, K pneumoniae) by inhibiting the production of enzymes that block carbapenem antibiotics, one of the more powerful classes of drugs in the antibiotic arsenal. In August 2017, meropenem/vaborbactam was FDA approved for complicated urinary tract infections (cUTI) caused by CRE.

The approval was based on data from a phase 3 multicenter, randomized, double-blind, double-dummy study, TANGO-I (n=550) in adults with cUTI, including those with pyelonephritis. The primary endpoint was overall cure or improvement and microbiologic outcome of eradication (defined as baseline bacterial pathogen reduced to 15</ref>


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!